TITLE

UNIGEN/INCA HEALTH TO DEVELOP PLANT-DERIVED HEALTH PRODUCTS

PUB. DATE
September 2004
SOURCE
Worldwide Biotech;Sep2004, Vol. 16 Issue 9, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the collaboration between plant-derived ingredients supplier Unigen Pharmaceuticals Inc. and agro-industrial company Inca Health for plant collection and product development. Details of the collaboration agreement; Information on their operations in the Peruvian Amazon Rainforest and Andes Mountains; Brief background of both companies.
ACCESSION #
14267603

 

Related Articles

  • MANAGING DRUG DISCOVERY ALLIANCES FOR SUCCESS. Laroia, Gaurav; Krishnan, Shiv // Research Technology Management;Sep/Oct2005, Vol. 48 Issue 5, p42 

    Although alliances are increasingly important to pharmaceutical companies, about 60 percent of alliances fail to produce their desired outcomes. Most of these failures are due to non-technical reasons. An analysis of Aventis' portfolio of drug discovery technology alliances suggests that...

  • Dormant Opportunity?  // Pharmaceutical Executive;Apr2005, Vol. 25 Issue 4, p32 

    Reports on the percentage of late-stage in-licensing deals among pharmaceutical firms in the U.S. Entry into strategic alliances with biotechnology companies; Cost implications of late-stage development; Shift in the risk/reward balance of the licensing process.

  • Increasing Productivity and Mitigating Risk with Networked Drug Development Alliances. Dietlin, Tim // Bio Outsourcing Asia;Jul2011, Vol. 4 Issue 1, p17 

    This article discusses the trend of biopharmaceutical companies pursuing networked drug development alliances, which connect biopharmaceutical companies with investors and clinical operations experts to create a drug development team. Attributions to the trend include the rising cost of drug...

  • Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case. Gutiérrez de Mesa Vázquez, Emma; Jiménez Martín, Juan Angel; Mascareñas, Juan // Journal of Commercial Biotechnology;Apr2006, Vol. 12 Issue 3, p229 

    The paper studies strategic alliances signed between traditional pharmaceutical companies (TPCs) and new biotechnology firms (NBFs) in Spain, on the initial basis that a firm's rate of new product development is a positive function of the number of strategic alliances that it has entered into....

  • Minimizing leakage of value from R&D alliances. Jones, Andrew // Nature Reviews Drug Discovery;Sep2007, Vol. 6 Issue 9, p711 

    Alliances, which are a key component of the research and development (R&D) strategies of most major pharmaceutical companies, demand significant management time and resources. There is no doubt that considerable value can be derived from R&D alliances, and much has been written about how...

  • Industry Partnerships: Changing the Way R&D Is Conducted. Spector, Ira // Applied Clinical Trials;Mar2006, Vol. 15 Issue 3, p46 

    No abstract available.

  • Innovative Early Phase Trial Design. Middle, Michelle // Applied Clinical Trials;Sep2010 Central Labs East Supplemnt, p10 

    The article focuses on the significance of incorporating innovative study design to achieve better development decisions in drug research and development. It stresses the need for biopharmaceutical companies to apply more innovative strategic recruitment approaches to make faster decisions about...

  • COMPANY SPOTLIGHT -- Pfizer.  // PharmaWatch: Cancer;Aug2007, Vol. 6 Issue 8, p20 

    The article features Pfizer, the world's largest research-based pharmaceutical company. According to the author, the company is engaged in discovering, developing, manufacturing and marketing of prescription medicines for humans and animals. He added that the company has a strong sales and...

  • COMPANY SPOTLIGHT - Solvay.  // PharmaWatch: Monthly Review;Jan2009, Vol. 8 Issue 1, p28 

    The article presents a corporate profile for Solvay Pharmaceuticals Inc., a developer of therapies for cardiovascular, gastroenterological, and neurological disorders. The company has operations in over 50 countries spanning Europe, the Americas, and Asia Pacific. The company has recently signed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics